ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas

Modern Pathology

Volumn 26, Issue 3, 2013, Pages 428-434

  Werner, Henrica M J ^a,b   Berg, Anna ^a,b   Wik, Elisabeth ^a,b   Birkeland, Even ^b   Krakstad, Camilla ^b   Kusonmano, Kanthida ^b,c   Petersen, Kjell ^c   Kalland, Karl H ^a,b   Oyan, Anne M ^a,b   Akslen, Lars A ^b   Trovik, Jone ^a,b   Salvesen, Helga B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Uni Research AS   (Norway)

Author keywords

ARID1A; carcinoma; endometrial

Indexed keywords

PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2;

AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL SURVIVAL; DISEASE SPECIFIC SURVIVAL; ENDOMETRIAL CARCINOGENESIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM HYPERPLASIA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

AGED; CARCINOMA, ENDOMETRIOID; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RNA, MESSENGER; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875218081     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.174     Document Type: Article

References (24)

1. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67:3093-3103.
2. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505.
3. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-231.
4. Wiegand KC. ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 2010;363:1532-1543.
5. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-1668.
6. Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11: 481-492.
7. Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell 2009;136:200-206.
8. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011; 35:625-632.
9. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011;224:328-333.
10. Katagiri A, Nakayama K, Rahman MT, et al. Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix. Int J Gynecol Cancer 2012;22: 208-212.
11. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012;33:100-103.
12. Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012;31:2090-2100.
13. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71:6718-6727.
14. Huang J, Zhao YL, Li Y, et al. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 2007;46:745-750.
15. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009;105:109.
16. Trovik J, Wik E, Stefansson IM, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011;17:3368-3377.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
18. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-1252.
19. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol 2008;18:89-97.
20. Engelsen IB, Stefansson IM, Akslen LA, et al. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199:e1-e7.
21. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-159.
22. Jechlinger M, Grunert S, Tamir IH, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003;22:7155-7169.
23. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012;25: 282-288.
24. Llaurado M, Ruiz A, Majem B, et al. Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinology 2012;25:244-255.